Contrafect Quick Ratio (CFRX) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Contrafect Corporation  (NASDAQ: CFRX)

Contrafect's Quick Ratio

CFRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0.46 below Contrafect's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 459 other companies have achieved higher Quick Ratio than Contrafect in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1643 to 2737.

Explain Quick Ratio?
How much Cash & cash equivalents CFRX´s has?
What are CFRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CFRX Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -49.63 % -20.77 % 18.22 % 75.12 % 150.82 %
Y / Y Cash & cash equivalent Change -69.33 % -47.18 % -67.15 % -74.8 % -72.13 %
Quick Ratio MRQ 0.46 0.91 0.73 0.68 0.76
CFRX's Total Ranking # 2737 # 1643 # 1957 # 2254 # 2212
Seq. Current Liabilities Change -26.29 % -16.77 % -5.91 % -12.75 % 15.95 %
Seq. Cash & cash equivalent Change -62.47 % 3.82 % 1.53 % -22.47 % -35.36 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 460
Healthcare Sector # 878
Overall Market # 2737


Quick Ratio Statistics
High Average Low
17.94 5.78 0.16
(Sep 30 2017)   (Jun 30 2014)




Financial Statements
Contrafect's Current Liabilities $ 12 Millions Visit CFRX's Balance sheet
Contrafect's Cash & cash equivalent $ 5 Millions Visit CFRX's Balance sheet
Source of CFRX's Sales Visit CFRX's Sales by Geography


Cumulative Contrafect's Quick Ratio

CFRX's Quick Ratio for the trailling 12 Months

CFRX Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -5.71 % 37.62 % 86.41 % 124.36 % 141.59 %
Y / Y Cash & cash equivalent TTM Growth -66.5 % -68.14 % -68.11 % -62.8 % -45.46 %
Quick Ratio TTM 0.71 0.76 0.88 1.27 2
Total Ranking TTM # 3958 # 3952 # 3932 # 1845 # 1208
Seq. Current Liabilities TTM Growth -14.7 % -5.04 % 3.69 % 12.25 % 24.51 %
Seq. Cash & cash equivalent TTM Growth -20.51 % -17.76 % -28.13 % -28.69 % -24.4 %

Quick ratio ranking by company, industry and sector >> Back to CFRX Financial Strength Comparisons >> Go to Compare CFRX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CFRX's Current Liabilities to $11.64 millions, cumulative Quick Ratio to 0.71 below the CFRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 531 other companies have achieved higher Quick Ratio than Contrafect. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3952 to 3958.

Explain Quick Ratio?
How much Cash & cash equivalents CFRX´s has?
What are CFRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 532
Healthcare Sector # 1072
Within the Market # 3958


trailing twelve months Quick Ratio Statistics
High Average Low
10.79 5.38 0.68
(Jun 30 2018)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Evotec Se  1.27 $ 662.556  Millions$ 520.322  Millions
Puma Biotechnology Inc   1.26 $ 85.029  Millions$ 67.362  Millions
Gyre Therapeutics Inc   1.25 $ 2.228  Millions$ 1.783  Millions
Oramed Pharmaceuticals Inc  1.23 $ 125.626  Millions$ 102.362  Millions
Organogenesis Holdings Inc   1.21 $ 98.226  Millions$ 81.482  Millions
Kyntra Bio Inc   1.20 $ 251.340  Millions$ 209.415  Millions
Amphastar Pharmaceuticals Inc   1.17 $ 302.076  Millions$ 257.963  Millions
Longeveron Inc   1.16 $ 3.933  Millions$ 3.394  Millions
Biodexa Pharmaceuticals Plc  1.15 $ 8.147  Millions$ 7.097  Millions
Aeon Biopharma inc   1.14 $ 16.177  Millions$ 14.177  Millions
Intercept Pharmaceuticals inc   1.13 $ 102.736  Millions$ 90.845  Millions
Enveric Biosciences Inc   1.10 $ 4.267  Millions$ 3.883  Millions
Zoetis Inc   1.09 $ 1,754.000  Millions$ 1,608.000  Millions
Durect Corp  1.06 $ 38.985  Millions$ 36.752  Millions
Nature s Sunshine Products inc   1.04 $ 76.036  Millions$ 73.312  Millions
Calliditas Therapeutics Ab  1.04 $ 104.676  Millions$ 100.997  Millions
Skye Bioscience Inc   1.04 $ 14.211  Millions$ 13.719  Millions
Aquestive Therapeutics Inc   1.04 $ 24.917  Millions$ 24.057  Millions
Abbott Laboratories  1.03 $ 7,047.000  Millions$ 6,809.000  Millions
Xencor Inc  0.99 $ 52.733  Millions$ 53.041  Millions
Kineta Inc   0.99 $ 7.562  Millions$ 7.615  Millions
Avadel Pharmaceuticals Plc  0.99 $ 52.641  Millions$ 53.138  Millions
Protokinetix Incorporated  0.98 $ 0.012  Millions$ 0.013  Millions
Inflarx N V  0.98 $ 18.547  Millions$ 18.866  Millions
Heron Therapeutics Inc   0.97 $ 77.412  Millions$ 79.745  Millions
Biomarin Pharmaceutical Inc  0.97 $ 1,125.845  Millions$ 1,163.223  Millions
Clever Leaves Holdings Inc   0.95 $ 6.472  Millions$ 6.847  Millions
Unicycive Therapeutics Inc  0.93 $ 14.345  Millions$ 15.456  Millions
Corbus Pharmaceuticals Holdings Inc   0.91 $ 28.733  Millions$ 31.542  Millions
60 Degrees Pharmaceuticals Inc   0.91 $ 2.219  Millions$ 2.446  Millions

Date modified: 2026-09-08T15:11:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.